Premium
Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents
Author(s) -
Schindler Rainer
Publication year - 2001
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-001-0755-z
Subject(s) - chemistry , chloral hydrate , pharmacology , enzyme , biochemistry , lovastatin , in vivo , enzyme inhibitor , cholesterol , medicine , biology , microbiology and biotechnology
Identification of inhibitors of retinyl ester hydrolase (RFH) would help to elucidate its role in vitamin A metabolism in vivo . By using standard incubation conditions, the effects of 215 drugs as potential inhibitors of purified pig and human liver REH when acting on micellar substrate retinyl palmitate were evaluated at 16.7, 167, and 1670 μM. Out of the compounds tested, 103 were inhibitors of the pig liver enzyme. The most potent compounds, in order of decreasing activity, were chloral hydrate, lovastatin, phytomenadione, alimemazine, physostigmine, thioridazine, phenoxybenzamine, probucol, cinnarizine, cyclandelate, amiodarone, flupenthixol, and naftidrofuryl; this order is roughly similar to that of their inhibition of human liver REH. Of the 10 tricyclic ring‐containing drugs tested, alimemazine was the most potent enzyme inhibitor. The concentrations necessary for 50% enzyme inhibition ranged from <2.6 up to >540 μM. Moreover, inhibitory kinetic studies showed that at least two pharmaceutica's, chloral hydrate and amiodarone, are potent REH inhibitors at therapeutically achievable serum concentrations. First‐pass metabolites were inactive as REH inhibitors compared to that of the parent compounds, in the cases of chloral hydrate, lovastatin, and cyclandelate.